RAD54L2
Helicase ARIP4
Also known as: ARIP4, ARIP4_HUMAN, KIAA0809, SRISNF2L
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9Y4B4
- Gene
- RAD54L2
- Ensembl
- ENSG00000164080
- Chromosome
- 3
- Canonical length
- 1467 aa
- Protein class
- Enzymes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
Predicted to enable ATP-dependent chromatin remodeler activity; protein kinase binding activity; and transcription coregulator activity. Predicted to be involved in chromatin organization. Predicted to act upstream of or within positive regulation of transcription by RNA polymerase II. Predicted to be located in nuclear speck. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
1467 residues, UniProt reviewed canonical sequence.
>Q9Y4B4|RAD54L2
1 MSDESASGSD PDLDPDVELE DAEEEEEEEE VAVEECDRDD EEDLLDDPSL EGMCGTEHAQ
61 LGEDGQQPPR CTSTTSSQSE PSEQLRRHQG KNLASEDPKK KRAQKPSHMR RNIRKLLRED
121 QLEPVTKAAQ QEELERRKRL EQQRKDYAAP IPTVPLEFLP EEIALRASDG PQLPPRVLAQ
181 EVICLDSSSG SEDEKSSRDE VIELSSGEED TLHIVDSSES VSEDDEEEEK GGTHVNDVLN
241 QRDALGRVLV NLNHPPEEEN VFLAPQLARA VKPHQIGGIR FLYDNLVESL ERFKTSSGFG
301 CILAHSMGLG KTLQVISFID VLFRHTPAKT VLAIVPVNTL QNWLAEFNMW LPPPEALPAD
361 NKPEEVQPRF FKVHILNDEH KTMASRAKVM ADWVSEGGVL LMGYEMYRLL TLKKSFATGR
421 PKKTKKRSHP VIIDLDEEDR QQEFRREFEK ALCRPGPDVV ICDEGHRIKN CQASTSQALK
481 NIRSRRRVVL TGYPLQNNLI EYWCMVDFVR PDFLGTRQEF SNMFERPILN GQCIDSTPQD
541 VRLMRYRSHV LHSLLEGFVQ RRGHTVLKIH LPAKEENVIL VRLSKIQRDL YTQFMDRFRD
601 CGSSGWLGLN PLKAFCVCCK IWNHPDVLYE ALQKESLANE QDLDVEELGS AGTSARCPPQ
661 GTKGKGEDST LASSMGEATN SKFLQGVGFN PFQERGNNIV TYEWAKDLLT NYQTGVLENS
721 PKMVLLFHLI EESVKLGDKI LVFSQSLSTL ALIEEFLGKR EVPCPPGTEG QGAQKWVRNI
781 SYFRLDGSTP AFERERLINQ FNDPSNLTTW LFLLSTRAGC LGVNLIGANR VVVFDASWNP
841 CHDAQAVCRV YRYGQKKPCY IYRLVADYTL EKKIYDRQIS KQGMSDRVVD DLNPMLNFTR
901 KEVENLLHFV EKEPAPQVSL NVKGIKESVL QLACLKYPHL ITKEPFEHES LLLNRKDHKL
961 TKAEKKAAKK SYEEDKRTSV PYTRPSYAQY YPASDQSLTS IPAFSQRNWQ PTLKGDEKPV
1021 ASVRPVQSTP IPMMPRHVPL GGSVSSASST NPSMNFPINY LQRAGVLVQK VVTTTDIVIP
1081 GLNSSTDVQA RINAGESIHI IRGTKGTYIR TSDGRIFAVR ATGKPKVPED GRMAASGSQG
1141 PSCESTSNGR HSASSPKAPD PEGLARPVSP DSPEIISELQ QYADVAAARE SRQSSPSTNA
1201 ALPGPPAQLM DSSAVPGTAL GTEPRLGGHC LNSSLLVTGQ PCGDRHPVLD LRGHKRKLAT
1261 PPAAQESSRR RSRKGHLPAP VQPYEHGYPV SGGFAMPPVS LNHNLTTPFT SQAGENSLFM
1321 GSTPSYYQLS NLLADARLVF PVTTDPLVPA GPVSSSSTAT SVTASNPSFM LNPSVPGILP
1381 SYSLPFSQPL LSEPRMFAPF PSPVLPSNLS RGMSIYPGYM SPHAGYPAGG LLRSQVPPFD
1441 SHEVAEVGFS SNDDEDKDDD VIEVTGKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RAD54L2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 7.3 nTPM
Expression across tissuesHPA
Tissue
- liver: 7.3 nTPM
- cerebellum: 7.2 nTPM
- retina: 7 nTPM
- skeletal muscle: 6.8 nTPM
- thymus: 5.8 nTPM
- bone marrow: 5.7 nTPM
Single-cell type
- renal collecting duct intercalated cells: 131 nCPM
- retinal horizontal cells: 130 nCPM
- myonuclei: 127 nCPM
- retinal ganglion cells: 124 nCPM
- retinal amacrine cells: 118 nCPM
- syncytiotrophoblasts: 116 nCPM
Immune cell
- MAIT T-cell: 3.5 nTPM
- non-classical monocyte: 3.5 nTPM
- gdT-cell: 3.3 nTPM
- basophil: 3.1 nTPM
- NK-cell: 3 nTPM
- memory CD4 T-cell: 2.9 nTPM
Brain region
- thalamus: 16 nTPM
- cerebellum: 16 nTPM
- cerebral cortex: 16 nTPM
- white matter: 15 nTPM
- basal ganglia: 15 nTPM
- midbrain: 15 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about RAD54L2.
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 183 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- TOP2 deficiency type 1
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.08
- gnomAD pLI
- 1
- gnomAD missense Z
- 3.13
- DepMap mean gene effect
- -0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- chromatin organization
- positive regulation of transcription by RNA polymerase II
- R-loop processing
- transcription elongation by RNA polymerase II
Molecular functions
- ATP binding
- ATP hydrolysis activity
- ATP-dependent chromatin remodeler activity
- DNA binding
- DNA helicase activity
- DNA/RNA helicase activity
- transcription coregulator activity
- ubiquitin protein ligase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- SNF2, N-terminal domain
- Helicase, C-terminal domain-like
- Helicase superfamily 1/2, ATP-binding domain
- P-loop containing nucleoside triphosphate hydrolase
- SNF2-like, N-terminal domain superfamily
- SNF2/RAD5-like, C-terminal helicase domain
- SNF2-related domain
- Helicase conserved C-terminal domain
- ARIP4, DEXH-box helicase domain
- ATPase ARIP4-like
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of RAD54L2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RAD54L2 as an antibody target. Whether an autoantibody or antibody against RAD54L2 could matter depends on whether native RAD54L2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RAD54L2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label RAD54L2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...